# A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

> **NCT00885508** · PHASE2 · UNKNOWN · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 85 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT00885508
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2015-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00885508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00885508, "A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00885508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*